Drug resistance

Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing

Tuesday, May 11, 2021 - 1:00pm

b'Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company.

Key Points: 
  • b'Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company.
  • Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor.
  • Proceeds of this financing will be used to accelerate clinical development of PhageBank\xe2\x84\xa2 phage therapies, as well as for general corporate purposes.\nAPT\xe2\x80\x99s PhageBank\xe2\x84\xa2 technology is a growing collection of hundreds of bacteriophage, collectively providing broad spectrum coverage against six of the highest priority multi-drug resistant bacterial pathogens.
  • Together, we believe we can bring PhageBank\xe2\x84\xa2 therapy into the mainstream, and work to solve one of the key challenges facing modern medicine, the growing problem of antibiotic-resistant bacteria.\xe2\x80\x9d\nAdaptive Phage Therapeutics is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

Greenbrook TMS Announces Preliminary First Quarter 2021 Operational and Financial Results

Tuesday, May 4, 2021 - 9:46pm

b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).

Key Points: 
  • b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).
  • We are proud of our team\xe2\x80\x99s efforts to continue to treat patients suffering from treatment resistant depression and obsessive-compulsive disorder during this difficult time.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.

Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens

Tuesday, May 4, 2021 - 1:00pm

\xe2\x80\x9cAntimicrobial resistance is one of the most urgent threats to global public health with the suite of ESKAPE pathogens posing a significant threat due to their virulence and rapid development of drug-resistance.

Key Points: 
  • \xe2\x80\x9cAntimicrobial resistance is one of the most urgent threats to global public health with the suite of ESKAPE pathogens posing a significant threat due to their virulence and rapid development of drug-resistance.
  • The slight variation (+/-) between one experiment to the next is likely due to small variance in the sensitivity of the instruments used in detection.
  • Further to this designation, RECCE\xc2\xae 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development.\nRecce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
  • Recce\xe2\x80\x99s anti-infective pipeline seeks to exploit the unique capabilities of RECCE\xc2\xae technologies targeting synergistic, unmet medical needs.\n"

DEINOVE, ESPCI Paris and INRAE awarded grant following the call for proposals of the French “Antibiotic resistance” Priority Research Program

Thursday, April 29, 2021 - 5:00pm

The evaluations reached the same conclusion: the microfluidic technology developed by DEINOVE is considered by the scientific and industrial community as a major asset for the screening and identification of new therapeutic solutions from bacterial biodiversity.\nAntibiotic resistance has become a major public health emergency that is now mobilizing the entire international community5, and of course France.

Key Points: 
  • The evaluations reached the same conclusion: the microfluidic technology developed by DEINOVE is considered by the scientific and industrial community as a major asset for the screening and identification of new therapeutic solutions from bacterial biodiversity.\nAntibiotic resistance has become a major public health emergency that is now mobilizing the entire international community5, and of course France.
  • By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance.
  • Today, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the world\xe2\x80\x99s first emergencies.
  • It aims to support \xe2\x80\x9cvery ambitious, structuring, long-term (3 to 6 years) research projects favoring interdisciplinarity and contributing to the emergence of synergies between different types of research (fundamental, environmental, clinical, translational), with the goal of stimulating and supporting the emergence of diagnostic, preventive and therapeutic innovations, and ultimately leading to a better use of antibiotics\xe2\x80\x9d.\n'

Specific Diagnostics Awarded Grant by the Department of Defense (DoD) to use Reveal for the Rapid Determination of the Antimicrobial Effectiveness of Bacteriophage

Thursday, April 29, 2021 - 3:09pm

With bacteria evolving resistance to antibiotics, driven in part by overuse, bacteriophage therapy represents a distinct and promising alternative to antibiotic therapy.\n\xe2\x80\x9cIn the age of antibiotic resistance, alternatives to antibiotics are increasingly needed,\xe2\x80\x9d said Dr. Paul A. Rhodes, Specific\xe2\x80\x99s CEO.

Key Points: 
  • With bacteria evolving resistance to antibiotics, driven in part by overuse, bacteriophage therapy represents a distinct and promising alternative to antibiotic therapy.\n\xe2\x80\x9cIn the age of antibiotic resistance, alternatives to antibiotics are increasingly needed,\xe2\x80\x9d said Dr. Paul A. Rhodes, Specific\xe2\x80\x99s CEO.
  • Its first commercial application applies this fundamental new capability to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions.
  • Specific is based in Mountain View, CA.
  • For press inquiries, please contact: Jeff Holman, press@specificdx.com\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005732/en/\n'

X-Biotix Therapeutics Announces Change in Corporate Strategy

Monday, April 26, 2021 - 12:00pm

b'X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of first-in-class antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, announced today a change in its strategy, which will include suspension of its current antibacterial research efforts.

Key Points: 
  • b'X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of first-in-class antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, announced today a change in its strategy, which will include suspension of its current antibacterial research efforts.
  • Resistant infections cost the US $20B in excess healthcare costs and $35B in lost productivity.
  • Co-founders of the company include distinguished faculty from Harvard Medical School, with expertise in biological mechanisms of cell envelope biosynthesis, antibiotic resistance and efflux.
  • For further information, please visit: http://www.x-biotixrx.com/\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005029/en/\n'

Phico Therapeutics Awarded up to $18.2 Million USD (c.£13.2 Million GBP) CARB-X Funding to Advance SASPject Antibacterial Therapy Through Phase 1 Clinical Trials

Monday, April 19, 2021 - 9:40am

\xc2\xa313.2 million GBP) from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.

Key Points: 
  • \xc2\xa313.2 million GBP) from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
  • The funding will support the progression of Phico\xe2\x80\x99s lead product SASPject\xe2\x84\xa2 PT3.9 through clinical trials with $5.3 million USD (circa.
  • \xc2\xa33.8 million GBP) available immediately and a further $12.9 million (circa.
  • Heather Fairhead, Phico Founder and CEO said: \xe2\x80\x9cTo receive funding from CARB-X is important validation for our SASPject technology platform and its potential in fighting bacterial resistance.

Onxeo to Present New Preclinical Data at AACR 2021

Thursday, April 8, 2021 - 5:41pm

Onxeo pioneered a new approach of anti-cancer treatment to tackle acquired drug resistance: the decoy agonist mechanism of action.

Key Points: 
  • Onxeo pioneered a new approach of anti-cancer treatment to tackle acquired drug resistance: the decoy agonist mechanism of action.
  • We now describe the mechanism of action of our OX400 molecules, designed to trap PARP proteins.
  • Our results provide a preclinical rationale for using OX400 molecules as immunomodulatory and metabolic exhauster agents, especially in appropriately molecularly selected patients with tumors showing metabolic deficiencies.
  • Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR).

Cūrza and the University of Florida Expand Collaboration to Include Bacterial Biothreats with DTRA Award

Thursday, April 1, 2021 - 1:42pm

SALT LAKE CITY, April 1, 2021 /PRNewswire/ --Crza Global, LLC (Crza) announced today that The Institute for Therapeutic Innovation (ITI) at the University of Florida has been awarded a $75M contract from the Defense Threat Reduction Agency (DTRA) in partnership with Crza.

Key Points: 
  • SALT LAKE CITY, April 1, 2021 /PRNewswire/ --Crza Global, LLC (Crza) announced today that The Institute for Therapeutic Innovation (ITI) at the University of Florida has been awarded a $75M contract from the Defense Threat Reduction Agency (DTRA) in partnership with Crza.
  • This program is aimed at the development of Crza's CZ-02 platform of antibiotics for the treatment of drug-resistant bacterial infections.
  • The CZ-02 platform represents a novel class of antibacterial agents with a unique mode of action.
  • Chad Testa, Ph.D., Vice President of Research at Crza will serve as Principal Investigator (PI) for Crza.

Worldwide Antibiotics Industry to 2026 - Featuring Pfizer, Bayer and Novartis Among Others

Tuesday, March 30, 2021 - 3:00pm

The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period.

Key Points: 
  • The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period.
  • Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.
  • The antibiotics market is growing owing to the increasing consumption of antibiotics in middle and lower-income countries, huge investments in R&D activities by pharmaceutical companies, and the increasing number of infectious diseases.
  • Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market.